Modern (NASDAQ: MRNA) said Tuesday that some cases in which patients appear to have allergic reactions to the coronavirus vaccine are being investigated. All of the reported incidents, in which people experienced reactions after their first beat of mRNA-1273, occurred at a vaccination clinic in San Diego. (The vaccine is administered in two doses, with the shots being given 21 days apart.)
The California Department of Health did not specify the exact number of people in the group who experienced these reactions, but dr. State epidemiologist Erica S. Pan said there were fewer than ten individuals over a 24-hour period.
In each case, the vaccine comes from one lot – no. 41L20A, which consists of more than 1.27 million doses distributed to approximately 1,700 vaccination sites in 37 states. More than 330,000 of them went to California. It is unknown at this time what he will do after leaving the post. To date, no similar groups of allergic reactions have been reported.
Image Source: Getty Images.
Following the reports regarding the San Diego group, dr. Pan on Sunday in a decision said she ‘[o]out of extreme caution “- issued a formal recommendation that health care providers immediately discontinue the use of vaccines from the premises in question. Pan promised to provide an update as her department learned more about the incidents.
As for Moderna, the company said it is working with federal health officials to investigate the possible causes of the reactions in California. It added that he is not aware of similar groups of incidents elsewhere.
To date, mRNA-1273 remains one of only two coronavirus vaccines approved for emergency use by the Food and Drug Administration. Like the others, Pfizer and BioNTechs BNT162b2, it is distributed throughout the country and the available supply is administered to the populations most at risk of COVID-19.
However, the deployment of the vaccine was slower than expected, with incoming President Joe Biden promising to accelerate the pace in the coming weeks and months.